Copyright
©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1215-1233
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1215
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1215
Term | Definition(s) |
Liver disorder | Serum ALT or AST > 2 × ULN, TB > 2 × ULN, ALP ≥ 2 ULN[75] |
Liver injury or acute liver injury | ALT and/or AST above 3 × ULN, ALP, GGT, and/or TB above 2 × ULN[9,34] |
ALT and/or AST ≥ 2 × ULN, with TB ≥ 2 × ULN and/or INR ≥ 1.7[70] | |
ALT levels above 3 × the ULN[28] | |
Mild liver injury | ALT above the ULN and below 2 × the ULN[25] |
Moderate liver injury | ALT between 2-5 × the ULN[25] |
Severe liver injury | ALT above 5 × the ULN[25] |
Any elevation of enzymes above 3 × the ULN and bilirubin above 2 × the ULN[5] | |
Liver test abnormalities | Elevation of the following serum liver enzymes: ALT > 40 U/L, AST > 40 U/L, GGT > 49 U/L, ALP > 135 U/L, and TB > 17.1 μmol/L[34] |
De novo LFTs abnormality | The occurrence of abnormal LFTs in patients with normal LFTs at admission[27] |
LFTs elevation | Increase in serum liver enzyme levels above the ULN[27,28] |
Mild LFTs elevations | Elevation 1-2 times above the ULN[25,34] |
Hepatocellular or hepatocyte type | The pattern of abnormal LFTs with predominantly elevated ALT and AST[27] |
Patients with raised ALT and/or AST more than 3 × the ULN[34] | |
AST/ALT activity is higher than the ALP/GGT activity, with liver enzyme activities calculated by multiples of their ULN[34] | |
Cholestatic or cholangiocyte type | Pattern of abnormal LFTs with predominantly elevated ALP and GGT[27] |
Patients with raised ALP or GGT 2 × the ULN[34] | |
ALP/GGT activity was higher than the AST/ALT activity, with the liver enzyme activities calculated by multiples of their ULN[34] | |
Mixed type | Mixed pattern when the extents of AST/ALT and ALP/GGT are similar[27] |
A combination of both ALT/AST elevated more than 3 × the ULN and ALP/GGT twice the ULN[34] | |
Drug-induced liver injury | Any elevation in liver enzymes or TB after the initiation of the drug in the absence of identified common causes of liver disease[5] |
- Citation: Omar AS, Kaddoura R, Orabi B, Hanoura S. Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. World J Hepatol 2021; 13(10): 1215-1233
- URL: https://www.wjgnet.com/1948-5182/full/v13/i10/1215.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i10.1215